help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-2436
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/9/5478    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Locatelli, M.
Right arrow Articles by Laws, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locatelli, M.
Right arrow Articles by Laws, E. R.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Neuroendocrinology and Pituitary
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 9 5478-5482
Copyright © 2005 by The Endocrine Society


CLINICAL REVIEW

CLINICAL REVIEW: The Strategy of Immediate Reoperation for Transsphenoidal Surgery for Cushing’s Disease

Marco Locatelli, Mary Lee Vance and Edward R. Laws

Department of Neurosciences, Ospedale Maggiore Policlinico, IRCCS (M.L.), 20122 Milan, Italy; and Department of Neurological Surgery, Department of Internal Medicine-Endocrinology, University of Virginia Health Sciences Center (M.L.V., E.R.L.), Charlottesville, Virginia 22908-0212

Address all correspondence and requests for reprints to: Dr. Edward R. Laws, Neurosurgery, Box 800212, University of Virginia Health System, Charlottesville, Virginia 22908-0212. E-mail: el5g{at}virginia.edu.


    Abstract
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Context: Transsphenoidal surgery is currently the primary therapeutic option for Cushing’s disease. Despite considerable initial success, 10–30% of patients fail to achieve lasting remission.

Evidence Acquisition: We evaluated a strategy of immediate reoperation in surgical failures judged by plasma cortisol levels that did not fall to 2 µg/dl or less within 72 h of surgery. Of 215 patients with presumed ACTH microadenomas, treated between 1993 and 2004, 12 met inclusion criteria and had prompt (within 15 d) reoperation for residual or missed ACTH microadenoma. These 12 patients represent 28% of those who did not have evidence of postoperative adrenal insufficiency.

Evidence Synthesis: Based on an outcome measure of sustained subnormal or normal plasma cortisol levels, eight of 12 patients (67%) achieved remission from the two operations. Adjunctive therapies (radiotherapy, gamma knife radiosurgery, and adrenalectomy) led to remission in another three patients. It is recognized that this outcome required either total hypophysectomy (one patient) or postoperative hypopituitarism (all patients in remission).

Conclusion: Magnetic resonance imaging was not usually helpful in determining therapeutic strategies; however, inferior petrosal sinus sampling was critical in providing confidence that the disease was of pituitary origin. A treatment algorithm is recommended, based on this study.


    Introduction
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
CUSHING’S DISEASE IS defined as hypercortisolism caused by an ACTH-secreting pituitary adenoma. The majority of these tumors are microadenomas with a diameter of less than 10 mm.

At present, the therapy of choice for Cushing’s disease is selective transsphenoidal resection of an ACTH-secreting microadenoma, with reported rates of postoperative remission varying from 70–85%, a mortality rate of less than 1%, and morbidity of approximately 1.8% in major published series (1, 2, 3, 4, 5, 6, 7, 8). Subnormal or undetectable levels of serum cortisol in the immediate postoperative period have been suggested as predictive of long-term remission (9, 10, 11, 12, 13, 14, 15). In cases of surgical failure, repeat exploration of the sella represents a treatment option that has been advocated by Hardy, Zervas, Trainer and colleagues, Oldfield and colleagues, and others (10, 16, 17, 18, 19). Repeat surgical treatment several days after the first transsphenoidal operation allows the surgeon to reexplore the sella with minimal additional trauma and no major concern about altered surgical anatomy.

Few data are available from the literature on the effect of repeat transsphenoidal surgery for persistent Cushing’s disease (10, 16, 18, 19). In particular, only two studies have focused on the results and complications of this procedure when performed within a short interval of time after the first operative procedure (10, 19).

The aim of this study was to determine the safety and the potential efficacy of redo transsphenoidal surgery within 15 d of the first such operation in patients with persistent postoperative hypercortisolism


    Patients and Methods
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Between August 1993 and January 2004, 215 patients underwent an initial transsphenoidal operation for a presumed pituitary microadenoma associated with Cushing’s disease at the neuroendocrine unit of the University of Virginia Health Sciences Center. Twelve of the patients fulfilled the criteria for the study: persistently high postoperative serum cortisol levels, followed by a second transsphenoidal operation for ACTH-secreting pituitary adenoma within 2 wk of the first procedure. One of these 12 patients presented with recurrent Cushing’s disease after initial surgery elsewhere. A retrospective analysis of the patients’ records was conducted. The study included nine women and three men with a mean age of 37.4 yr (range, 21–61 yr). The mean follow-up was 27 months (range, 4–76 months).

The major symptoms and their frequency were typical (6) and reflected the severity of disease in this subset of Cushing’s disease patients; the average duration of symptoms was 40.2 months (range, 3–84 months).

The diagnosis of Cushing’s disease was based upon currently accepted laboratory criteria (20). The endocrinological tests were performed both at the neuroendocrine unit of the University of Virginia and at other institutions. In the latter case the results were confirmed by endocrinologists in our Pituitary/Neuroendocrine Center.

The diagnostic protocol included a magnetic resonance imaging (MRI) study of the sellar region, which was performed in all cases before surgery. The contrast-enhanced MRI scans (pituitary protocol) were examined by the reporting radiologist and the operating neurosurgeon. They were defined as negative when a normal gland and a normal sellar region were present, equivocal when it was possible to recognize subtle changes suggestive, but not diagnostic, of adenoma, and positive when a tumor was identified.

The indication for inferior petrosal sinus sampling (IPSS) was related to the results of the endocrinological tests and the MRI. Eleven patients underwent IPSS preoperatively. This study was considered confirmatory of pituitary Cushing’s disease when the basal central to peripheral ACTH ratio was 2 or more or the CRH-stimulated central to peripheral ACTH ratio was 3 or more. The test was considered positive for lateralization when the side to side ACTH ratio was greater than 1.4 (21, 22).

The patients had unremarkable past medical histories, except for one who had undergone transsphenoidal surgery elsewhere 2 yr before admission to our institution (she had developed recurrent Cushing’s disease after 1 yr of clinical remission). Two patients had had previous thyroid surgery for Graves’ disease and goiter, respectively.

A single surgeon performed each microsurgical transsphenoidal operation via the endonasal [with the hemitransfixion or the pushover technique as previously described (23)] or sublabial route. When appropriate, endoscopic assistance was also used. Perioperative corticosteroid therapy was not administered. Our standard postoperative assessment after both the initial and second procedures consisted of the measurement of serum cortisol every 6 h for at least 3 d (14) or until serum cortisol was 2 µg/dl or less.

Patients were defined as being in remission when they developed clinical symptoms and laboratory evidence of adrenal insufficiency (serum cortisol, ≤2 µg/dl). The level of postoperative serum cortisol for definition of remission was 2 µg/dl or less.

The second transsphenoidal operation was performed within 15 d of the first procedure; the median interval between the two procedures was 5.08 d (range, 3–14 d). Serum cortisol was again measured every 6 h after surgery to assess the outcome. If the serum cortisol declined to 2 µg/dl or less, glucocorticoid replacement therapy was instituted immediately. The patients were followed regularly to assess adrenal function and clinical symptoms.

Of the 215 patients treated by initial transsphenoidal surgery, a total of 43 (20%) failed to achieve postoperative remission. Twelve of these patients had immediate reoperation. Among the others, five had undergone total hypophysectomy and did not have obvious ectopic parasellar pituitary tumor on MRI; they were not offered another operation. Seven were treated with radiation therapy, all but one with the gamma knife; four of these had locally invasive tumors. Six had not had IPSS and were followed. Thirteen patients either refused repeat surgery or were not offered another procedure, usually because they had a decrease toward normal serum cortisol levels. Desire for fertility and concern about full pituitary replacement therapy were also factors considered. Of the 32 patients who were not treated by immediate reexploration, none was later operated upon transsphenoidally.


    Results
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
The preoperative laboratory findings are presented in Table 1Go. In nine patients the MRI was defined as equivocal, in one it was clearly positive for the presence of a microadenoma, and two patients had normal imaging studies (negative). IPSS was performed in 11 of the 12 patients; in five cases excess ACTH production was lateralized to the right, and in three cases to the left, and there was no lateralization gradient in three patients. IPSS was not performed in the patient with the positive MRI scan who had typical clinical and diagnostic laboratory features of Cushing’s disease.


View this table:
[in this window]
[in a new window]
 
TABLE 1. Preoperative evaluation of 12 patients with Cushing’s disease due to presumed ACTH microadenoma

 
At initial surgery 11 patients were operated upon using the endonasal approach; in three cases the hemitransfixion submucosal technique was used, and in eight cases a septal pushover was employed. In one previously operated upon patient a sublabial approach was used. In two cases endoscopic assisted surgery was performed. At initial surgery the procedure was selective adenomectomy in three cases and hemihypophysectomy in nine cases.

Complications of the initial transsphenoidal operation consisted of an alar tear in one case. Two patients had intraoperative cerebrospinal fluid (CSF) leaks successfully repaired using an abdominal fat graft.

In all cases the gross surgical findings were thought by the surgeon to be consistent with the presence of pathological tissue compatible with a microadenoma (size range, 2–8 mm). The initial pathology reports, however, were positive for ACTH adenoma in two cases and negative in 10 (Table 2Go).


View this table:
[in this window]
[in a new window]
 
TABLE 2. Surgical and pathology findings of 12 patients with Cushing’s disease due to presumed ACTH microadenoma

 
Postoperative cortisol levels were above the 2 µg/ml cutoff level in all 12 patients.

The second operation was performed via the endonasal route in 10 cases (two cases by the hemitransfixion submucosal method and eight by the septal pushover technique). A sublabial approach was chosen in two cases. In 10 cases a total hypophysectomy was performed, and in two cases a subtotal hypophysectomy was completed (Table 3Go).


View this table:
[in this window]
[in a new window]
 
TABLE 3. Postoperative evaluation of 12 patients with Cushing’s disease due to presumed ACTH microadenoma, after second transsphenoidal operation

 
The complications of immediate reoperative surgery consisted of 10 cases of intraoperative CSF leak (all repaired by fat graft), a case of suspected transient meningitis (remission of symptoms within 2 d of antibiotic therapy), a superficial infection at a fat graft donor site, one case of nonfatal pulmonary embolism from a presumed deep venous thrombosis, and a urinary tract infection. The latter two complications occurred 5 d after the second operation in the same patient who had severe Cushing’s disease and cardiomyopathy.

At follow-up, eight of the 12 patients (67%) were in remission after the two transsphenoidal operations; three other patients achieved remission after subsequent treatment (one patient underwent conventional radiotherapy of the sellar region, one bilateral adrenalectomy, and one gamma knife radiosurgery, followed by bilateral adrenalectomy). These three patients received medical therapy with ketoconazole, but it was discontinued in two patients because of liver toxicity and in one patient who failed to achieve a significant reduction of 24-h urinary free cortisol. The remaining patient, who had severe Cushing’s disease, died of heart failure before adjunctive therapy could be given. All 11 surviving patients are receiving appropriate hormonal replacement therapy.


    Discussion
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Despite the high success rate of transsphenoidal surgery for Cushing’s disease caused by ACTH microadenomas, it is estimated that 10–30% of the patients fail to achieve long-term remission (18, 24, 25). Once a correct diagnosis of Cushing’s disease is made and ectopic sources of ACTH/CRH or pseudo-Cushing syndromes are excluded, two reasons for surgical failure (recurrent or persistent pituitary tumor and consequent endocrinopathy) can be identified. The first is the presence of residual tumor remaining hidden in the gland or ectopic in the intrasellar or perisellar region (25); the second is residual invasive tumor within the dura mater of the sella turcica or of the cavernous sinus (24, 25).

In patients who are not cured by surgery, four therapeutic options remain: repeat transsphenoidal operation, medical therapy, radiation therapy (conventional or radiosurgery), and bilateral adrenalectomy. The optimum treatment or sequence of different treatments has not yet been established. Because of the serious effects of Cushing’s disease, hypercortisolism must be treated as promptly and effectively as possible with the fewest adverse effects.

The efficacy and toxicity of medical and radiation therapy have been assessed previously as well as those of repeat reexploration of the sella (10, 18, 19). The role of immediate reoperation (within 15 d of the first operation) has rarely been investigated. Previous studies include those by Trainer et al. (10), who studied 10 patients with repeat surgery within 10 d, with a 70% remission rate. Ram and colleagues (19) reported on 17 patients who had a second operation 7–46 d after the first, with a 53% remission rate. The rationale of immediate reoperative transsphenoidal surgery is to remove the presumed residual accessible tumor or gland without the disadvantages (altered anatomy and scar tissue) of delayed surgery. This strategy, when successful, also limits the consequences of progressive Cushing’s disease. The presence of a positive IPSS test provides the surgeon with a significantly enhanced level of confidence when considering a secondary operative procedure.

After the two transsphenoidal operations, eight of our 12 patients (67%) are alive and in remission following surgical management alone. Three additional patients achieved remission after combined therapy.

Every reported series of transsphenoidal surgery for presumed ACTH-secreting microadenomas includes some 15–30% of patients in whom the histopathology is negative for tumor. This occurs even in patients with positive IPSS, and a significant proportion of these patients may achieve postoperative remission of Cushing’s disease. In Ram’s report of Oldfield’s series (19), 11 of the 17 patients had no tumor found at the second procedure, and six of the 11 achieved remission. In our series, eight of the 12 patients had no tumor found at the second operation, and five had surgical remissions. This phenomenon is often explained by the loss of the critical pathological material in the operative suction apparatus or in transport or handling in the pathology laboratory. It remains a vexing problem in the analysis of outcome.

In our patients the surgical complications consisted of one case of pulmonary embolism due to deep venous thrombosis, one urinary tract infection, a superficial abdominal (fat graft) wound infection, and one patient with suspected transient meningitis and an alar tear. An intraoperative CSF leak occurred in two patients during the first operation and in 10 patients during the immediate redo operation. There were no cases of persistent or delayed postoperative CSF leak. Moreover, no cases of operative mortality (30 d) or of classical major morbidity (vascular injury/occlusion, sellar abscess, complicated meningitis, sellar pneumatocele, cranial nerve palsy, visual loss, or CSF rhinorrhea) occurred.

This study highlights a number of different considerations. First, an interesting point arises from the MRI data. A large number of patients had nondiagnostic studies (11 of 12 cases). This finding partially explains the high number of IPSS procedures performed (11 of 12). Considering the reluctance of a surgeon to operate on a patient with an equivocal or negative MRI scan, a positive IPSS study is without any doubt a powerful factor, allowing the surgeon to feel more confident in recommending an operation.

It is generally true in neurosurgery and certainly true for transsphenoidal surgery that complication rates are higher with reoperations, and outcomes are generally less favorable than after the initial operation (26, 27). Although the small number of patients can be considered a limitation of this study, the balance between positive results and surgical complications suggests that immediate reoperative transsphenoidal surgery for pituitary Cushing’s should be considered a safe and effective therapeutic strategy.

The management of patients with Cushing’s disease who fail to achieve postoperative remission is difficult, poorly defined, and often discouraging. Accordingly, a therapeutic algorithm for the management of Cushing’s disease incorporating immediate reoperative transsphenoidal surgery in this process has been developed (Fig 1Go). This algorithm reflects our experience and our outcome data.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 1. Algorithm for the management of Cushing’s disease. TS, Transsphenoidal surgery.

 
This algorithm is designed to be a guide rather than a rigid protocol. As mentioned above, many factors must be considered in making a recommendation for repeat surgery. These include the patient’s willingness to consider reoperation, severity of disease, desire for fertility, concern about replacement therapy, and risk factors related to Cushing’s and other concurrent disease. Obviously each patient is different, and each deserves a carefully considered recommendation for additional therapy.

It is important to note that successful management of this relatively uncommon, but often devastating, disease is most likely to occur in collaborative centers where experience in diagnosis, surgery, and adjunctive therapy is available.


    Acknowledgments
 
We are grateful to Ms. Barbara Behnke for her expert assistance with the preparation of the manuscript.


    Footnotes
 
First Published Online June 14, 2005

Abbreviations: CSF, Cerebrospinal fluid; IPSS, inferior petrosal sinus sampling; MRI, magnetic resonance imaging.

Received December 13, 2004.

Accepted June 6, 2005.


    References
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 

  1. Semple CG, Thompson JA, Teasdale GM 1984 Transsphenoidal microsurgery for Cushing’s disease. Clin Endocrinol (Oxf) 21:621–629[Medline]
  2. Guilhaume B, Bertagna X, Thomsen M, Bricaire C, Vila-Porcile E, Olivier L, Racadot J, Derome P, Laudat MH, Girard F 1988 Transsphenoidal pituitary surgery for the treatment of Cushing’s disease: results in 64 patients and long term follow up studies J Clin Endocrinol Metab 66:1056–1064
  3. Melby JC 1988 Therapy of Cushing’s disease: a consensus for pituitary microsurgery. Ann Intern Med 109:445–446
  4. Lamberts SWJ, van der Lely AJ, de Herder WW 1995 Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing’s disease. Considerations concerning preoperative medical treatment and the long follow up. J Clin Endocrinol Metab 80:3111–3113[CrossRef][Medline]
  5. Massoud AF, Powell M, Williams RA, Hindmarsh PC, Brook CG 1997 Transsphenoidal surgery for pituitary tumours. Arch Dis Child 76:398–404[Abstract/Free Full Text]
  6. Reitmeyer M, Vance ML, Laws Jr ER 2002 The neurosurgical management of Cushing’s disease. Mol Cell Endocrinol. 197 73–79
  7. Shimon I, Ram Z, Cohen ZR, Hadani M 2002 Transsphenoidal surgery for Cushing’s disease: endocrinological follow up monitoring of 82 patients. Neurosurgery 51:57–62[CrossRef][Medline]
  8. Hoybye C, Grenback E, Thoren M, Hulting A, Lundblad L, Von Holst H, Angaard A 2004 Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases. J Neurosurg 100:634–638[Medline]
  9. Fahlbusch R, Buchfelder M, Muller OA 1986 Transsphenoidal surgery for Cushing’s disease. J R Soc Med 79:262–269[Abstract]
  10. Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Sabage MO, Afshar F, Besser M 1993 Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as a definition of successful treatment. Clin Endocrinol (Oxf) 38:73–78[Medline]
  11. Toms GC, McCarthy MI, Niven MJ, Orteu CH, King TT, Monson JP 1993 Predicting relapse after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 76:291–294[Abstract]
  12. Bochicchio D, Losa M, Buchfelder M 1995 Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey group. J Clin Endocrinol Metab 80:3114–3120[Abstract]
  13. Chee GH, Mathias DB, James RA, Kendal-Taylor P 2001 Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf) 54:617–626[CrossRef][Medline]
  14. Simmons NE, Alden TD, Thorner MO, Laws Jr ER 2001 Serum cortisol response to transsphenoidal surgery for Cushing’s disease. J Neurosurg 95:1–8
  15. Rollin AFS, Ferreira NP, Junges M, Gross JL, Czepielewski MA 2004 Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing’s disease. J Clin Endocrinol Metab 89:1131–1139[Abstract/Free Full Text]
  16. Hardy J 1982 Cushing’s disease: 50 years later. Can J Neurol Sci 4:375–380
  17. Zervas NT 1980 Reflections on the surgery of the pituitary. Clin Neurosurg 27:124–132[Medline]
  18. Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler GB, Loriaux DL 1989 Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71:520–527[Medline]
  19. Ram Z, Lynette KN, Gordon Jr BC, Chrousos GP, Doppman JL, Oldfield E 1994 Early repeat surgery for persistent Cushing’s disease. J Neurosurg 80:37–45[Medline]
  20. Arnaldi A, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman K, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602[Abstract/Free Full Text]
  21. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler Jr GB, Loriaux DL 1991 Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 325:897–905[Abstract]
  22. McCartney CR, Vance ML 2001 Inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing’s syndrome. Endocrinologist 11:388–398
  23. Wilson WR, Laws Jr ER 1992 Transnasal septal displacement approach for secondary transsphenoidal pituitary surgery. Laryngoscope 102:951–953[Medline]
  24. Tindall G, Herring CJ, Clarck RV, Adams DA, Watts NB 1990 Cushing’s disease: results of transsphenoidal microsurgery with emphasis on surgical failures. J Neurosurg 72:363–369[Medline]
  25. Dickerman RD, Oldfield E 2002 Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. J Neurosurg 97:1343–1349[Medline]
  26. Semple PL, Laws Jr ER 1999 Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing’s disease. J Neurosurg 91:175–179[CrossRef]
  27. Laws Jr ER, Fode NC, Redmond MJ 1985 Transsphenoidal surgery following unsuccessful prior therapy. J Neurosurg 63:823–829[Medline]



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. G. Patil, D. M. Prevedello, S. P. Lad, M. L. Vance, M. O. Thorner, L. Katznelson, and E. R. Laws Jr.
Late Recurrences of Cushing's Disease after Initial Successful Transsphenoidal Surgery
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 358 - 362.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Pouratian, D. M. Prevedello, J. Jagannathan, M. B. Lopes, M. L. Vance, and E. R. Laws Jr.
Outcomes and Management of Patients with Cushing's Disease without Pathological Confirmation of Tumor Resection after Transsphenoidal Surgery
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3383 - 3388.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. W. Findling and H. Raff
Cushing's Syndrome: Important Issues in Diagnosis and Management
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3746 - 3753.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/9/5478    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Locatelli, M.
Right arrow Articles by Laws, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locatelli, M.
Right arrow Articles by Laws, E. R.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Neuroendocrinology and Pituitary


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals